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Objective: Chronic levodopa (L-dopa) treatment in Parkinson’s disease (PD) is often associated with the development
of motor complications, but the corresponding epidemiological data is rare in Chinese PD patients. The present survey
was to investigate the prevalence rate of wearing-off (WO) and dyskinesia among the patients with PD in China.
Methods: From May 2012 to October 2012, a 3-step registry survey for wearing off (WO) and dyskinesia patients with
PD receiving levodopa therapy was performed simultaneously at 28 movement disorders clinics in China.
Results: There were 1,558 PD patients fulfilling the inclusion criteria. Among them, 1,051 had at least one positive
response of 9-item wearing off questionnaire (WOQ-9), 724 and 160 patients were finally diagnosed with WO and
dyskinesia by movement disorders specialists, respectively. The overall prevalence rates of WO and dyskinesia were
46.5% (95% CI 44.0% - 48.9%) and 10.3% (95% CI 8.8% - 11.8%), respectively. The mean score of WOQ-9 for those with
WO was 3.8 (SD = 1.8), with movement slowness being the most common motor symptoms and pain/aching being
the most common non-motor symptoms. Better improvement of motor symptoms (n = 354, 87.8%) and long-term
disease control and drug selection (n = 288, 71.5%) were the two most frequently considered factors when movement
disorders specialists adjusted therapeutic strategies for patients with WO.
Conclusions: This survey provided the first multi-center epidemiological data of motor complications among PD
patients on L-dopa therapy from mainland China. WO prevalence rate among Chinese PD patients was in line with,
while dyskinesia prevalence rate was lower than previous reports from other Countries.
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Up to now, Levodopa (L-dopa) is still recognized as the
most widely used and effective medication for Parkinson’s
disease (PD), but long period therapy is often associated
with the development of motor complications such as
wearing-off (WO) and dyskinesia, which brought not only
challenges for neurologists, but also impaired daily living
and poor life quality of PD patients. Generally, the first* Correspondence: chen_sd@medmail.com.cn
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unless otherwise stated.motor complication is predictable WO in advancing PD,
that is, a recurrence of motor and non-motor symptoms
preceding scheduled doses of anti-PD medication that
usually improved after the next dosage [1]. Early identifi-
cation of such condition is of great importance for the
timely optimized treatment of PD.
Cumulative evidence indicated that approximately 40%
patients treated with L-dopa for 4–6 years experienced
motor complications in Western Countries [2,3], whereas,
the corresponding epidemiological data was rare in Chinese
PD patients. Heterogeneity exists in previous reports from
Hong Kong [4] and Suzhou [5], China. Moreover, both of
them were based on single center data with limited sampletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cially WO in Chinese PD patients deserves further inves-
tigation. Since the 9-item wearing-off questionnaire
(WOQ-9) is a simple and highly-sensitive diagnostic
screening scale for WO [6,7], we considered that WO
was rarely present in patients with zero point on WOQ-9
as recommended by Movement Disorders Society (MDS)
in 2011 [8].
Once recognized, WO can be effectively managed via
a number of therapeutic options, including adjustments
of L-dopa dosage and dosage form, adjunctive therapy
with catechol-O-methyltransferase (COMT) inhibitors,
monoamine oxidase-B (MAO-B) inhibitors and dopamine
agonists. Nevertheless, clinical experience and treatment
concepts from movement disorders specialists also play
critical roles in the optimized therapy of WO [9,10]. Since
PD is still an incurable disease, current therapy could only
improve the symptoms, the long-term outcome should be
considered when selecting treatment strategy.
Therefore, we conducted a multi-center registry sur-
vey in mainland China to explore the prevalence and
characteristics of WO among outpatients with PD re-
ceiving L-dopa therapy. In addition, the factors consid-
ered by movement disorders specialists when making
therapeutic choices for WO patients and the prevalence
rate of dyskinesia were also investigated.
Subjects and methods
Survey setting
From May, 2012 to October, 2012, this cross-sectional,
non-interventional registry study was performed simul-
taneously at 28 movement disorders clinics in tertiary
hospitals located in capital cities with over 1,000 beds
and the highest medical and academic levels in China.
Patients with PD who were willing to participate, pro-
vided written informed consent, and met the entry cri-
teria were enrolled at each clinic. During each visit,
firstly, preliminary screening for eligible PD patients was
done by study nurses before evaluated by the neurolo-
gists; Secondly, WOQ-9 and basic information registry
form were completed by the informed patients, it could
be completed with the aid of study nurse; Finally, compre-
hensive case report form (CRF) was recorded for patients
with at least one positive item (WOQ-9 ≥ 1). The final
diagnoses of WO and dyskinesia were made by movement
disorders specialists. WO was accepted as the shortening
of the duration of L-dopa benefit to less than 4 h for every
L-dopa dose given as reference [11]. Dyskinesia was de-
fined as an involuntary choreatic movement involving the
muscles of limbs, neck, trunk, or rarely face during the
“on” period of patients who displayed prominent improve-
ment of their parkinsonian symptoms [11].
The study was sponsored by Chinese Parkinson’s Dis-
ease & Movement Disorders Society, Neurology Branchof Chinese Medical Association, with approval from the
Research Ethics Committee, Rui Jin Hospital affiliated
to Shanghai Jiao Tong University School of Medicine,
Shanghai, China.
Survey design
Subjects with clinical diagnosed PD based on the United
Kingdom PD Brain Bank Criteria [12], were eligible for
inclusion into the study if they had L-dopa medication
at least 30 days and written informed consent. Patients
with secondary parkinsonism and atypical parkinsonism
syndrome (such as multiple system atrophy, progressive
supranuclear palsy, dementia of lewy body, cortical basal
ganglia degeneration, etc.) were excluded. Subjects were
also excluded if they withdraw the survey underway.
9-item wearing-off questionnaire
For those eligible PD patients, WOQ-9 was completed,
which covered both motor and non-motor symptoms of
WO [13]. For each item, patients reported whether a
symptom was present and whether it improved after the
subsequent dose of anti-PD medications. If both were
positive, one score was obtained. WOQ-9 defined the
possible presence of WO as at least one score obtained.
Basic information registry form
For enrolled PD patients, demographic parameters such
as age, gender, smoking, education, height, body weight
and concomitant diseases were recorded on basic infor-
mation registry form. Clinical characteristics collected
included onset age, disease duration, L-dopa duration and
medications history. L-dopa dosage and L-dopa equivalent
dosage (LED) were calculated as reported by a previous
report [14].
Case report form (CRF)
CRF was completed for PD patients with more than one
positive item of WOQ-9. Besides information collected
in basic registry form, the motor subscale of the Unified
Parkinson’s Disease Rating Scale (UPDRS-III) was used
to evaluate motor function [15]. For patients with motor
fluctuation, they were assessed during the “on” stage.
Modified Abnormal Involuntary Movement Scale (mAIMS)
was used to screen dyskinesia [16]. An Activities of Daily
Living (ADL) questionnaire was completed by the patients
or their caregivers or spouse, which included six physical
and eight instrumental ADLs [17]. If movement disorders
specialists considered the current treatment protocol of
patients with WO needed adjustment, the factors con-
cerned should be selected below: 1) long-term disease
control and drug selection, 2) limited economic condition
of patients, 3) better improvement of motor symptoms,
4) prior consideration of tolerance and safety of medica-
tions, 5) whether the drug was available in hospitals or
Figure 2 Percentage of PD with WO and dyskinesia stratified
by L-dopa therapy duration (n = 1488).
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8) others. All the assessments were performed by move-
ment disorders specialists during face-to-face interviews
with the patients. Researchers were systematically trained
before the investigation.
Statistical analysis
Statistical analysis was performed with SPSS, the overall
and L-dopa duration specific prevalence rates of WO
and dyskinesia were estimated and the corresponding
95% confidence interval (CI) were calculated based on
the Poisson distribution. The independent sample t test
and Chi-square analysis were employed for comparing
group means and categorical data, respectively. Pearson
correlation analysis was used for evaluating bivariate
correlation. All p values were 2-sided and values < 0.05
were considered statistically significant.
Results
WO prevalence, characteristics and associated factors
Figure 1 described the screening and enrollment proto-
col through the survey. Of the 1,826 patients screened,
1,558 were enrolled in this study for further evaluation.
A total of 268 were excluded, the majority of them were
due to protocol violations (n = 159) and withdraw under-
way (n = 80). The protocol violation was caused by mis-
diagnosis of PD. Among these enrolled patients, a total
of 507 had negative finding of WOQ-9. Thus, 1,051 with
score > =1 of WOQ-9 went into the evaluation stage of
movement disorders specialists. The demographic and
clinical data of enrolled patients and those with CRF
evaluation were summarized in Additional file 1: Table S1.
Finally, 724 patients were diagnosed with WO. The overall
prevalence rate of WO was 46.5% (95% CI: 44.0% - 48.9%).
The prevalence of WO increased with the prolonged
duration of L-dopa treatment (p = 0.0013), as shown in
Figure 2. 29.0% PD patents with L-dopa duration less than
one year experienced WO, the corresponding values were
33.5%, 50.2%, 60.3% and 68.3% for those with L-dopa dur-
ation 1–2.5 years, 2.5 - 5 years, 5–10 years and more thanFigure 1 Flow chart of patients with WO through the survey.
WOQ-9, the 9-item wearing off questionnaire; WO, wearing-off.10 years, respectively. The probability of detecting WO by
movement disorders specialists was strongly associated
with the positive response number of WOQ-9 (p = 0.0002).
Among these 724 confirmed patients with WO, the
mean score of WOQ-9 was 3.8 (SD = 1.8). Overall, motor
WO symptoms outweighed the non-motor WO symp-
toms (Figure 3). As the most common motor symptoms
WO, slowness of movement was identified by up to 83.0%
of patients. Whereas, the most common non-motor WO
symptoms was pain/aching occupying 31.1% of subjects.
Compared with those without WO, patients with WO
had more proportion of female patients (p < 0.0422), youn-
ger age (p < 0.0001), lower weight (p < 0.0090), earlier on-
set age (p < 0.0001), longer disease duration (p < 0.0001),
longer L-dopa therapy duration (p < 0.0001), larger L-dopa
dosage and LED (p < 0.0001), more severe UPDRS-III (p <
0.0001) and disabled ADL (p < 0.0001). Subgroup analysis
for patients with CRF evaluation showed that 19.5% of pa-
tients with WO had dyskinesia as confirmed by movement
disorders specialists, the proportion of which was signifi-
cantly higher than that without WO (6.48%) (p < 0.0001).
With respect to medications, there were more proportions
of patients with WO receiving levodopa-benserazide (p <
0.0001), levodopa-carbidopa (p = 0.0002), Piribedil (p =
0.0013) and entacapone (p < 0.0001), relative to the WO
negative group (Table 1).
Factors considered when adjusting therapeutic strategies
for WO patients
Among 724 patients with WO, 55.7% (n = 403) of them
needed therapy adjustment according to the opinion of
movement disorders specialists. The factors concerned
by movement disorder specialists for WO patients, in
rank order, were as follows: better improvement of motor
symptoms (n = 354, 87.8%), long-term disease control and
drug selection (n = 288, 71.5%), prior consideration of tol-
erance and safety of medications (n = 54, 13.4%), limited
Figure 3 Frequency of motor and non-motor WO symptoms with respect to WOQ-9 among WO patients (n = 724).
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tients’ choices (n = 14, 3.5%) and the price of medications
(n = 11, 2.7%).
Dyskinesia prevalence and associated factors
Among 1,558 enrolled patients, 160 of them were finally
diagnosed with dyskinesia by movement disorders spe-
cialists. The overall prevalence rate of dyskinesia was
10.3% (95% CI: 8.8% - 11.8%). Dyskinesia prevalence rate
was positively associated with L-dopa treatment duration
(p = 0.0072) as shown in Figure 2.
Compared with those without dyskinesia, patients with
dyskinesia had younger age (p = 0.0016), earlier onset
age (p < 0.0001), lower weight (p < 0.0001), longer disease
duration (p < 0.0001), longer L-dopa therapy duration (p <
0.0001), larger amount of L-dopa dosage and LED (p <
0.0001) and more disabled ADL (p < 0.0001). Subgroup
analysis for patients with CRF evaluation showed that up
to 88.5% of patients with dyskinesia had WO, which was
significantly higher than those without dyskinesia (65.9%)
(p < 0.0001). In terms of medications, there were more
proportions of patients with dyskinesia receiving levodopa-
carbidopa (p < 0.0001), piribedil (p < 0.0001) and entaca-
pone (p = 0.0003), in comparison with those without
dyskinesia. However, regarding the proportion of levodopa-
benserazide, there was no difference between the two
groups (p = 0.9094) (Table 1).
Discussion
This cross-sectional, multi-center survey showed that,
for Chinese PD outpatients with L-dopa therapy, totally
46.5% and 10.3% suffered from WO and dyskinesia, re-
spectively. Compared with those reported in other popu-
lations, the prevalence rate of WO was similar while theprevalence rate of dyskinesia was obviously lower (Table 2).
The underlying reasons may be as follows: 1) Methodo-
logical differences: in theory, results from current muti-
center study and the other three studies [18-20] were
more accurate than those from single center reports
[2,4,5,11,21,22]. The current study revealed WO preva-
lence (46.5%) in China was a little bit higher than that in
USA & Europe (motor fluctuation 43.9%) [19] and lower
than that in Czech Republic(66.7%) [18]. 2) Variations on
baseline characteristics of enrolled patients: Several
prospective studies indicated L-dopa dosage and disease
duration were two important predictive factors of the
development of dyskinesia [3,23,24]. Both items of enrolled
patients in the present study were lower than previous
reports in North America, Europe and some Asian
Countries, which may explain the low prevalence of
dyskinesia in China. 3) Race factor and genetic predispos-
ition: Olanow et al. found both WO and dyskinesia
occurred more frequently in North American versus
European sites [24]. It was reported in recent years that
several genetic variations (such as COMT Val158Met [25],
BDNF val66met [26], mu opioid receptor polymorphism
and dopamine D2 receptor intronic dinucleotide repeat
polymorphism [27]) were associated with the occurrence
of motor complications, especially for dyskinesia. So the
specific susceptible loci associated with motor complica-
tions in Chinese patients warrant further investigation.
Since WO is generally the first motor complication to
develop, early identification of such condition is of great
importance for the optimized therapy. This survey showed
that approximately 67.5% of Chinese PD patients with
more than one positive response of WOQ-9 were finally
diagnosed with WO by movement disorders specialists,
confirming that WOQ-9 was fit for clinical screening for
Table 1 Differences between enrolled patients with and without WO and dyskinesia
Items WO Dyskinesia
With (n = 724) Without (n = 834) P value With (n = 160) Without (n = 1398) P value
Age, years <.0001 0.0016
Mean ± SD 63.8 ± 9.6 66.5 ± 9.3 63.0 ± 9.5 65.5 ± 9.5
n (missing) 710(14) 815(19) 156(4) 1369(29)
Gender, Female 0.0422 0.1959
n (%) 347(47.9) 356(42.8) 80(50.0) 623(44.6)
n (missing) 724(0) 832(2) 160(0) 1396(2)
Height, cm 0.2230 0.2203
Mean ± SD 164.1 ± 7.8 164.6 ± 7.7 163.6 ± 8.3 164.4 ± 7.7
n (missing) 717(7) 826(8) 157(3) 1386(12)
Weight, kg 0.0090 <.0001
Mean ± SD 60.9 ± 11.1 62.3 ± 10.7 58.46 ± 10.12 62.01 ± 10.91
n (missing) 720(4) 826(8) 158(2) 1388(10)
Onset age, years <.0001 <.0001
Mean ± SD 57.3 ± 9.9 62.3 ± 9.5 54.9 ± 9.9 60.5 ± 9.9
n (missing) 711(13) 783(51) 156(4) 1338(60)
Disease duration, years <.0001 <.0001
Mean ± SD 6.7 ± 4.4 4.2 ± 3.7 8.2 ± 5.5 5.1 ± 4.0
n (missing) 713(11) 796(38) 155(5) 1354(44)
UPDRS-III* <.0001 0.1678
Mean ± SD 19.0 ± 8.4 15.6 ± 6.7 18.8 ± 9.1 17.8 ± 7.9
n (missing) 724(0) 327(0) 160(0) 891(0)
L-dopa duration, years <.0001 <.0001
Mean ± SD 5.1 ± 3.9 3.3 ± 3.5 5.9 ± 4.7 3.9 ± 3.7
n (missing) 703(21) 785(49) 151(9) 1337(61)
L-dopa dosage <.0001 <.0001
Mean ± SD 478.5 ± 247.0 355.4 ± 191.5 581.7 ± 311.4 393.8 ± 207.7
n (missing) 724(0) 834(0) 160(0) 1398(0)
≤400 mg/d n (%) 359(37.2) 607(62.8) <.0001 52(5.4) 914(94.6) <.0001
400-600 mg/d n (%) 234(56.5) 180(43.5) 54(13.0) 360(87.0)
>600 mg/d n (%) 131(73.6) 47(26.4) 54(30.3) 124(69.7)
LED <.0001 <.0001
Mean ± SD 558.4 ± 281.7 414.4 ± 216.0 707.8 ± 336.9 455.4 ± 234.9
n (missing) 724(0) 834(0) 160(0) 1398(0)
ADL* <.0001 <.0001
Mean ± SD 28.4 ± 12.9 21.0 ± 9.6 31.3 ± 13.6 25.1 ± 12.0
n (missing) 721(3) 326(1) 160(0) 887(4)
Medications for PD, n (%)
Levodopa-benserazide 647(89.4) 682(81.8) <.0001 136(85.0) 1193(85.3) 0.9094
Levodopa-carbidopa 285(39.4) 253(30.3) 0.0002 87(54.4) 451(32.3) <.0001
Pramipexole 245(33.8) 266(31.9) 0.4147 58(36.3) 453(32.4) 0.3262
Piribedil 196(27.1) 168(20.1) 0.0013 66(41.3) 298(21.3) <.0001
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Table 1 Differences between enrolled patients with and without WO and dyskinesia (Continued)
Entacapone 152(21.0) 109(13.1) <.0001 43(26.9) 218(15.6) 0.0003
Selegiline 17(2.4) 32(3.8) 0.0931 4(2.5) 45(3.2) 0.6216
Trihexyphenidyl 101(13.9) 114(13.7) 0.8725 17(10.6) 198(14.2) 0.2190
Amantadine 174(24.0) 182(21.8) 0.3000 46(28.8) 310(22.2) 0.0606
*based on patients with complete CRF; WO Wearing-off, UPDRS Unified Parkinson’s Disease Rating Scale, LED, Levodopa equivalent dosage, ADL Activities of
Daily Living.
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to WO phenomenology, totally, motor WO symptoms
outweighed the non-motor WO symptoms, as shown in
the present survey and Western Countries’ surveys.
Movement slowness was the most common motor WO
symptoms, whereas, pain/aching was the most common
non-motor WO symptoms in our results. This may be a
little bit difference from those in Western Countries. Stacy
and co-workers in 2005 found tremor and tiredness were
the most frequent motor and non-motor fluctuation
symptom, respectively [19]. The potential reason of this
discrepancy needs to be further investigated. However,
both of these symptoms may provide important informa-
tion for the identification of WO in clinical practice. It
was reported that non-motor fluctuation may involve a
greater degree of disability than motor fluctuation [28].
Therefore, more attention should be paid for the recogni-
tion of non-motor fluctuation in future research.
Our survey indicated that young onset age, low body
weight, large amount of LED, long duration of disease
and L-dopa therapy were associated with motor complica-
tions in Chinese PD patients with impaired ADL. Other
than those with dyskinesia, there were more female and
severe motor disabled patients with WO. All these results
were consistent with previous cross-sectional investiga-
tions by others and a recent prospective study reported by
Olanow and co-workers [24]. Based on these studies, clini-





UK 87 Community based 40.0(MF)
China 63 Hospital based, single center 44.4
USA & Europe 289 Hospital based, multi-center 43.9*(MF)
Turkey 555 Hospital based, single center 46.3
Chile 124 Hospital based, single center 52.0
Hong Kong 98 Hospital based, single center 74.5(MF)
Czech Republic 563 Hospital based, multi-center 66.7
Japan 1453 Hospital based, single center 44.7
Italy 617 Hospital based, multi-center 56.9
China 1558 Hospital based, multi-center 46.5
*WO diagnosis according to UPDRS-IV, MF Motor fluctuation.with low doses and increase the dosage in small incre-
ments in the long run. Besides, it may also be important
to consider the weight of patients when prescribing
L-dopa. In terms of medications, patients with motor
complications took more proportions of L-dopa, piribedil
and entacapone. Since this was a cross-sectional study, a
proportion of patients may have already employed the ad-
junctive therapy (such as piribedil or entacapone) for their
existed motor complications, we could not draw a conclu-
sion whether these alternative drugs were risk or protect-
ive factors of motor complications in the present survey.
As expected, better improvement of motor symptoms
(87.8%) and long-term disease control and drug selection
(71.5%) were the two frequent considered factors when
movement disorders specialists adjusted therapeutic
strategies for patients with WO. This may be partially
benefited from the clinical practice of Chinese PD treat-
ment guidelines, since published in 2006 and 2009, re-
spectively [9]. The L-dopa treatment concept–using the
lowest dose that provides the satisfactory clinical control
to delay the occurrence of motor complication, especially
among PD patients with young onset age, influenced more
and more clinical doctors with its popularity.
There were some limitations of our study. Firstly, pa-
tients with no positive response of WOQ-9 did not go
to neurologists’ evaluation in the present survey. Besides,
only choreatic dyskinesias were counted which could
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10.3 Present study
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and dyskinesia might be a little bit underestimated. Sec-
ondly, as a cross-sectional study, only associated factors
of motor complications could be found in the present
investigation. Since only patients with more than one
point of WOQ-9 had UPDRS motor evaluation, we did
not perform multiple logistic regression analysis to ex-
plore the independent influential factor of WO and dys-
kinesia. To better clarify its independent predictive
factors, prospective cohort studies are needed in future.
Conclusions
We performed the first multi-center registry survey of
WO among Chinese patients with PD on L-dopa ther-
apy. The prevalence rate of WO found in our study was
similar to, while dyskinesia was relatively lower than
those in other Asian and Caucasian Countries, and dif-
ferent reasons such as methodological difference, L-dopa
dosage and genetic susceptibility may contribute to this
result.
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Beijing Tiantan Hospital affiliated to Capital Medical
University; Wei-Guo Liu, Nanjing Brain Hospital affiliated
to Nanjing Medical University; Xiao-Guang Luo, The First
Hospital of China Medical University; Xiao-Chun Chen,
Union Xiehe Hospital, Fujian Medical University; An-Mu
Xie, The Affiliated Hospital of Medical College Qingdao
University; Chun-Feng Liu, The Second Affiliated Hospital
of Soochow University; Zhen-Guo Liu, Xinhua Hospital
affiliated to Shanghai Jiao Tong University School of
Medicine; Yi-Ming liu, Qilu Hospital of Shandong Univer-
sity; Jian Wang, Huashan Hospital affiliated to Fudan Uni-
versity; Hui-Fang Shuang, West China Hospital, Sichuan
University; Biao Chen, Xuanwu Hospital of Capital Med-
ical University; Bei-Sha Tang, Xiangya Hospital, Central
South University; Xing-Yue Hu, Shaoyifu Hospital affili-
ated to Zhejiang University School of Medicine; Li-Juan
Wang, Guangdong General Hospital; Bao-Rong Zhang,
The Second Affiliated Hospital of Zhejiang University
School of Medicine; Min Ye, Nanjing BenQ medical
Center; Hai-Bo Chen, Peking Hospital; Xin-Hua Wan,
Peking Union Medical College Hospital; Ming-Wei Wang,
The First Hospital of Hebei Medical University; Xian-Wen
Chen, The First Affiliated Hospital of Anhui Medical Uni-
versity; Yan Chen, General Hospital Affiliated to Tianjing
medical University; Guo-Guang Peng, The First Affiliated
Hospital of Chongqing Medical University; Zhen-FuWang,The General Hospital of Chinese People’s Liberation Army;
Ping-Yi Xu, The First Affiliated Hospital, Sun Yat-Sen
University; Sheng-Gang Sun, Union Hospital of Tongji
Medical College of Huazhong University of Science and
Technology; Xiang-Ru Sun, The First Hospital affiliated to
Beijing University.
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Additional file 1: Table S1. Demographic and basic clinical information
of enrolled patients and those with complete CRF.
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